Your Bones Aren't Responding to Exercise. Here's Why.

Your VDR gene codes for the vitamin D receptor, a protein in your intestines and bones that acts like a lock. When vitamin D binds to it, calcium absorption switches on. Without a functioning VDR, you can drink all the fortified milk you want and still not absorb enough calcium to mineralize new bone.

The problem: roughly 30 to 50% of the population carries a BsmI, FokI, or TaqI variant in VDR that reduces this receptor’s efficiency. A VDR variant can cut your calcium absorption by 40% or more, meaning you literally cannot pull enough calcium from your diet no matter how much you consume. This is why some people need double the recommended daily calcium just to maintain baseline bone health.

For you, this means weight-bearing exercise works harder to stress bone tissue, signaling it to strengthen, but the mineralization step never completes. Your bones remain porous and weak even though you’re sending all the right signals.

Bone is roughly 70% mineral and 30% organic matrix. That organic matrix is mostly collagen type I, the same protein that gives skin elasticity and tendons their strength. COL1A1 determines the quality and cross-linking of this collagen, which directly determines fracture resistance.

The Sp1 site variant (rs1800012), found in roughly 15 to 20% of the population, reduces collagen cross-linking efficiency. People with this variant produce collagen that looks normal on blood tests but is mechanically weaker and more susceptible to breaking. Imagine a rope made of individual fibers that aren’t woven tightly together. It may look like a rope, but it snaps under tension.

You can have excellent bone mineral density on a scan and still fracture easily because your collagen scaffold is structurally compromised. Weight-bearing exercise stresses the collagen matrix, but if it’s poorly cross-linked, the stress can accumulate into microfractures.

Estrogen is the primary bone protector in women. It works by binding to estrogen receptors on osteoclasts (bone-destroying cells) and silencing them. In post-menopausal women, estrogen drops and osteoclasts go wild, accelerating bone loss. The ESR1 gene codes for estrogen receptor alpha, which determines how sensitive your bones are to whatever estrogen is still circulating.

Roughly 40% of the population carries PvuII or XbaI variants in ESR1 that reduce receptor sensitivity. Even if your circulating estrogen is normal, your bone cells respond to it poorly, behaving as if estrogen levels are already low. This is why some women lose bone rapidly even before menopause and why post-menopausal bone loss accelerates faster in some women than others.

For you, weight-bearing exercise can’t fully compensate for poor estrogen signaling at the bone level. Exercise triggers osteoblasts (bone builders), but estrogen silence osteoclasts. Without both working together, the balance tips toward resorption.

LRP5 is a co-receptor in the Wnt signaling pathway, one of the most powerful bone-building signals in the body. When Wnt ligands bind to LRP5, osteoblasts (bone-forming cells) get activated and proliferate. This is why Wnt agonists are being developed as bone-building drugs. A functional LRP5 pathway is essential for achieving peak bone mass in youth and maintaining it later.

Common LRP5 variants reduce the efficiency of Wnt signaling. People with these variants have fewer osteoblasts being recruited and activated in response to mechanical stress, meaning weight-bearing exercise triggers weaker bone-building responses. You could be running, lifting, or hiking but signaling your osteoblasts at half intensity compared to someone without the variant.

The consequence is that despite consistent weight-bearing exercise, you plateau at a lower peak bone mass and don’t see the bone density gains others achieve.

MTHFR controls folate metabolism and homocysteine regulation. Elevated homocysteine directly impairs collagen cross-linking, weakening the bone matrix’s organic component. This is a separate mechanism from COL1A1, but the outcome is similar: bone that looks dense on a scan but breaks easily.

The C677T variant, present in roughly 40% of people with European ancestry, reduces MTHFR enzyme efficiency by 40 to 70%. This enzyme inefficiency causes homocysteine to accumulate, which directly interferes with lysine and proline cross-linking in bone collagen. Even if you’re getting enough calcium and have strong collagen genes, elevated homocysteine undermines the structural integrity of that collagen.

You might feel like your bones are brittle because they biochemically are. The mineralization may be adequate, but the matrix scaffold is compromised at the molecular level.

Bone is constantly being torn down and rebuilt. RANKL (receptor activator of nuclear factor kappa B ligand) is the signal that tells osteoclasts to remove old bone. OPG (osteoprotegerin) is the brake pedal that stops them. This system is designed to be balanced. But in people with RANKL variants or with inflammatory conditions, the balance tips toward excessive bone resorption.

Common RANKL variants, found throughout the population at varying frequencies, reduce the efficiency of osteoclast regulation or increase baseline RANKL expression. The result is a remodeling imbalance where bone is broken down faster than it can be replaced, creating a net loss of bone density over time. Exercise signals bone to strengthen, but if RANKL is constantly telling osteoclasts to work overtime, the gains are immediately erased.

You might be doing everything right and still watching your bone density decline year after year because the resorption signal is simply louder than the building signal.